Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYTHIC: Placebo Versus Macrolide Antibiotics for Mycoplasma Pneumoniae Infection in Children With Community-acquired Pneumonia
NCT06325293Recruiting
- Start
- Jan 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of azithromycin in community acquired pneumonia (CAP) and Mycoplasma pneumonia (2 arms). Primary endpoints: Days to normalization of all vital signs at 28 days and Community-acquired pneumonia (CAP)-related change in patient care status at 28 days. Started Jan 2025; status: recruiting.
02
Drugs
azithromycin
03
Conditions
community acquired pneumonia (CAP)Mycoplasma pneumonia
Beyond the preview
Go deeper on NCT06325293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06325293.